Through breastfeeding, the transfer of immune factors from the mother to the infant, which had started already *in utero*, continues postnatally.^[@bib1],\ [@bib2]^ These maternal factors protect the infant from infections and assist in the development of the infant\'s intestinal mucosa, gut microflora and own defences.^[@bib3],\ [@bib4],\ [@bib5]^ Indeed, breastfed infants have a lower risk of necrotizing enterocolitis, and reduced susceptibility to gastrointestinal, respiratory and other infections than formula-fed infants.^[@bib2],\ [@bib3],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9],\ [@bib10]^ The immunomodulatory function of breastmilk is thought to be mediated by both cellular and biochemical components, including maternal leukocytes and biomolecules with antimicrobial, anti-inflammatory, antioxidant and prebiotic activities.^[@bib6],\ [@bib9],\ [@bib11],\ [@bib12]^ However, the underlying mechanisms through which these factors act to so consistently confer protection are yet poorly understood.^[@bib13],\ [@bib14]^

In addition to being a well-balanced source of amino acids specifically serving the growth needs of the human infant, breastmilk proteins, such as immunoglobulins and lactoferrin, exert antimicrobial and immunomodulatory activities, enhancing the infant\'s defence against pathogens.^[@bib15]^ Secretory IgA (sIgA), the major human milk immunoglobulin, confers maternal acquired immunity to the infant.^[@bib16]^ IgG and IgM antibodies are also present in breastmilk but in much lower concentrations, exerting protective roles in the infant.^[@bib13]^ Despite variations observed in the concentrations of immunomodulatory bioactive factors in breastmilk both within and between women,^[@bib13]^ the normal baseline levels under healthy conditions and infection-stimulated responses during the course of lactation are not well understood.

The immunoreactive biochemical factors of breastmilk are complemented by maternal leukocytes, which are thought to confer active immunity and influence the development of immunocompetence in the infant, as well as protect the mammary gland from infection.^[@bib7],\ [@bib17],\ [@bib18],\ [@bib19]^ Colostrum and mature breastmilk contain various cell types, including mature epithelial cells, progenitor cells, stem cells and leukocytes.^[@bib20],\ [@bib21],\ [@bib22]^ While some are endogenous to the mammary gland, others (for example, leukocytes) migrate to this site from the lymphatic vessels and systemic circulation.^[@bib23]^ Breastmilk leukocytes are thought to be somewhat different from their blood counterparts^[@bib24],\ [@bib25],\ [@bib26]^ and to exert immunomodulatory functions in the infant via phagocytosis, secretion of antimicrobial factors, such as cytokines and immunoglobulins, or antigen presentation.^[@bib9],\ [@bib18],\ [@bib19],\ [@bib27]^ And they are thought to perform these functions not only inside the gastrointestinal tract of the infant, but also in distant tissues where they are transferred via the systemic circulation.^[@bib1],\ [@bib9],\ [@bib24]^

The concentrations of immune factors in breastmilk are by no means stable. Breastmilk is a complex and dynamic fluid, with a changing composition that responds to infant feeding^[@bib28]^ and the stage of lactation.^[@bib14],\ [@bib15]^ Most previous studies on breastmilk leukocytes focused on colostrum/early lactation milk, while very little is known about the leukocyte range in mature breastmilk under healthy conditions and how it changes together with biochemical components in response to infections of the mother, and indeed the infant. Evidence suggests that the health status of both the mother and the infant may influence breastmilk cellular content,^[@bib29]^ suggesting an immunological link between the mothers and their breastfeeding infants. This may partly explain the great variability of breastmilk leukocyte content among women reported in the literature. An additional explanation may be provided by the basic microscopy-based leukocyte identification techniques previously utilized, which pose limitations in the context of breastmilk leukocytes, some of which share morphological traits with mammary epithelial subtypes.^[@bib30]^ Thus, more accurate and consistent methodology is needed to quantify breastmilk leukocyte content and composition, and establish the baseline levels of immune factors in breastmilk of healthy dyads during lactation and how these may be altered by infection. This is a critical step to improving understanding of viral transmission during the breastfeeding period, and how leukocytes and other breastmilk components protect the infant.^[@bib31],\ [@bib32]^ In addition to the infant, the breast is also thought to be protected by the influx of leukocytes to mammary infection sites.^[@bib19]^ Therefore, the leukocyte status of breastmilk may provide a novel means for assessing the health status of the lactating breast, the only metabolically significant organ in the body, without clinical tests to assess its normality. In this context, it is of interest that similar tests are routinely used by the dairy industry to assess the quality of bovine milk and the presence of intramammary infection in the dairy cow.^[@bib33],\ [@bib34]^ To address the question of whether the leukocyte content of breastmilk can be used to assess the health status of the breastfeeding dyad, we examined whether there is a baseline range of leukocytes in mature breastmilk from healthy dyads and how this is influenced by different infections of the mother and/or the infant.

Results
=======

Healthy mother/infant dyads have a low baseline level of leukocytes in breastmilk
---------------------------------------------------------------------------------

Fluorescence-activated cell sorting (FACS) quantification of CD45 protein expression was done by an analytic gating strategy that excluded interference by dead/dying cells and/or fat globules ([Supplementary Figure S1a](#sup1){ref-type="supplementary-material"}). Although colostrum always contained considerable levels of leukocytes (13.2--70.4% leukocytes of total milk cells; 32 175--784 080 viable leukocytes per ml colostrum), these rapidly decreased toward the end of the first week postpartum to reach a baseline level in transitional milk (0--1.7% leukocytes of total milk cells; 0--3450 viable leukocytes per ml milk) and mature breastmilk (0--1.5% leukocytes of total milk cells; 0--1151 viable leukocytes per ml milk) when both the breastfeeding mother and infant were healthy ([Figure 1a](#fig1){ref-type="fig"}; [Supplementary Figures S1a,b](#sup1){ref-type="supplementary-material"}; [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). The low baseline level of mature breastmilk leukocytes under healthy conditions was maintained even at late lactation stages (years 2--4 postpartum) ([Table 1](#tbl1){ref-type="table"}) and was found to fluctuate within certain limits (0--2% leukocytes of total milk cells) both between and within individuals.

Infections of the mother/infant dyad stimulate a leukocyte response in breastmilk
---------------------------------------------------------------------------------

Infections of the breast, other organs or general maternal infections all stimulated a leukocyte response in breastmilk that ranged from 0.7% (sore breast) to 93.6% (mastitis) leukocytes of total milk cells (*P*\<0.001) ([Figures 1b--d](#fig1){ref-type="fig"}; [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). Severe breast infections, such as mastitis, stimulated a greater leukocyte response (*P*\<0.001). The effect of systemic and other organ infections on breastmilk leukocyte content was in agreement with the observed effect of mastitis of one breast on the breastmilk leukocyte content of the other (mastitis-free) breast ([Figure 1b](#fig1){ref-type="fig"}). A small increase in breastmilk leukocyte content was also observed when only the infant had an infection, while the mother was asymptomatic (*P*=0.046) ([Figure 1b](#fig1){ref-type="fig"}). No difference was seen between pre- and post-infection baseline leukocyte levels (*P*=0.48) ([Figure 1b](#fig1){ref-type="fig"}; [Supplementary Figure S1c](#sup1){ref-type="supplementary-material"}). Importantly, the leukocyte response to infection and recovery, as well as transition from colostrum to transitional milk, was rapid ([Figures 1a and b](#fig1){ref-type="fig"}). In contrast to leukocytes, milk total cell and viable cell contents did not significantly vary by health status or milk type ([Figure 1c](#fig1){ref-type="fig"}; [Table 2](#tbl2){ref-type="table"}). However, total cell content significantly increased (*P*=0.002) with lactation stage ([Figure 1d](#fig1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). The latter did not significantly influence % cell viability (*P*=0.09) ([Figure 1d](#fig1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). Milk leukocyte content did not significantly change after week 1 postpartum as long as the dyad was healthy (*P*=0.36) ([Figure 1d](#fig1){ref-type="fig"}). Leukocytes in breastmilk from women with mastitis contained monocytes, macrophages, dendritic cells, T-helper cells, cytotoxic T cells, natural killer cells and a small population of B lymphocytes ([Figure 2a](#fig2){ref-type="fig"}). Infection-stimulated leukocytes contained activated cell subsets that responded to viral antigens and PHA in culture with increased proliferation rate and altered expression of interleukin (IL)-6, IL-17A, interferon-γ and tumor necrosis factor-α ([Figures 2b and c](#fig2){ref-type="fig"}).

Infections of the mother/infant dyad stimulate a humoral immune response in breastmilk
--------------------------------------------------------------------------------------

In addition to breastmilk leukocyte response to maternal/infant infection, a less consistent but often significant humoral immune response was observed. sIgA was higher in colostrum compared with mature breastmilk from healthy dyads (*P*\<0.001) ([Figure 3a](#fig3){ref-type="fig"}; [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). In mature breastmilk, sIgA concentration increased only during infection of the mother and/or the infant (*P*=0.034) ([Figure 3a](#fig3){ref-type="fig"}; [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}), and this increase was stronger in organ-specific infections ([Table 3](#tbl3){ref-type="table"}). IgG concentration was generally low (2.8--22.9 μg ml^−1^) ([Table 1](#tbl1){ref-type="table"}), with no marked difference between colostrum and mature breastmilk from healthy dyads (*P*=0.71), and marginally increased with maternal or infant infection (*P*=0.048) ([Figure 3a](#fig3){ref-type="fig"}; [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). No difference was seen between pre- and post-infection baseline sIgA and IgG levels (*P*=0.37 and *P*=0.66, respectively). In few subjects, sIgA and/or IgG concentration was higher in the post-recovery sample, suggesting a potential delayed response to infection ([Supplementary Figure S1d](#sup1){ref-type="supplementary-material"}). In contrast to sIgA and IgG, no significant changes were seen for IgM or lactoferrin with infections (*P*=0.61 and *P*=0.66, respectively), although colostrum and transitional milk concentrations were higher than in mature breastmilk from healthy dyads (*P*\<0.001) ([Figure 3a](#fig3){ref-type="fig"}; [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). Infant age had a profound effect on breastmilk sIgA (*P*\<0.001), IgG (*P*=0.045) and lactoferrin (*P*=0.008) concentrations ([Figure 3b](#fig3){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). In the data set of healthy dyads, an initial sIgA decrease from colostrum to mature breastmilk up to around week 25 and a plateau until week 50 was followed by an increase in later lactation ([Figure 3b](#fig3){ref-type="fig"}). IgG concentration was constant for the first 60 weeks postpartum, but increased in later lactation ([Figure 3b](#fig3){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). Lactoferrin concentration initially decreased up to around week 25 and then increased as lactation progressed ([Figure 3b](#fig3){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). Involution seemed to influence the biochemical and total cellular, but not the leukocyte, content of breastmilk, with marked increases in these components ([Table 1](#tbl1){ref-type="table"}).

Breastmilk immune response differs between infection types
----------------------------------------------------------

Breastmilk leukocyte content was significantly higher for all infection types compared with the healthy baseline, with the weakest response seen for infant infections (*P*=0.046), and the strongest response for breast infections (*P*\<0.001), particularly mastitis ([Table 3](#tbl3){ref-type="table"}). A decrease in % cell viability with infection was observed only for maternal colds (*P*=0.025). Total breastmilk cell content increased during breast-related infections, being associated with a stronger leukocyte response in mastitis compared with less severe breast infections ([Table 3](#tbl3){ref-type="table"}). Principal component analysis (PCA) demonstrated distinctive response patterns for specific sample types. Mastitis (*N*=5) clustered separately from other infections, being strongly associated with breastmilk leukocyte content ([Figure 4a](#fig4){ref-type="fig"}). Weaning (*N*=1) and menstruation (*N*=1) were separate from the rest of the healthy data set. Colostrum also tended to cluster differently from the healthy data set ([Figure 4a](#fig4){ref-type="fig"}).

Non-exclusive breastfeeding is associated with lower baseline milk leukocyte levels
-----------------------------------------------------------------------------------

Breastfeeding status significantly related to milk leukocyte content. Under healthy conditions, the baseline breastmilk leukocyte content was lower in non-exclusively breastfed infants (*P*=0.024), the majority of whom received breastmilk with no detectable leukocytes ([Figure 4b](#fig4){ref-type="fig"}). The infection response in both exclusive and non-exclusive breastfeeding dyads was such that similar leukocyte levels were seen during infection ([Figure 4b](#fig4){ref-type="fig"}).

Discussion
==========

Breastmilk has long been known to contain leukocytes,^[@bib30]^ but their regulation and variation between individuals and stages of lactation are not well established. Here, we show that mature breastmilk from healthy mother/infant dyads retains a low baseline level of 0--2% leukocytes during lactation. Infections of the breast, other organs or general infections of the mother or the infant stimulate a rapid breastmilk leukocyte response, with restoration of the baseline levels upon recovery. We suggest that the general health status of the dyad, recent health history, environmental factors that they are exposed to and/or the severity of an infection determine the variation in breastmilk leukocyte content during the healthy and infection statuses. Other factors not considered in the present study, such as the menstrual cycle, may also influence breastmilk leukocyte content and warrant further investigation.

The humoral breastmilk response to infection was less consistent and more variable than the cellular response, with sIgA and IgG showing the most consistent humoral response. The most abundant immunoglobulin in breastmilk was sIgA, followed by IgM and IgG, consistent with previous literature.^[@bib35],\ [@bib36],\ [@bib37],\ [@bib38],\ [@bib39]^ The variation observed in humoral breastmilk responses to infection could be explained by a differential response of each immunological biochemical factor to different infections, a delayed response in some dyads/infection types, or an underlying health condition of the mother and/or the infant during collection of the post-recovery samples. The latter is unlikely as no evidence for a leukocyte response was found in these post-recovery samples. Of note, the most consistent humoral immune response was observed during mastitis, which represents a severe infection of the breast, and is in agreement with the strong leukocyte response.

Indeed, mastitis recorded the highest milk leukocyte contents, which sometimes delayed to return to baseline levels, particularly when there was a delay in diagnosis and treatment. Mastitis is common among breastfeeding women in early stages of lactation, being associated with inadequate emptying of the breast.^[@bib40],\ [@bib41],\ [@bib42]^ This can stimulate leukocyte trafficking to the breast, explaining the high levels of milk leukocytes detected, with distinct profiles including activated T cells that responded to antigen stimulation via proliferation and cytokine production. Milder breast infections showed contrasting breastmilk responses ([Table 3](#tbl3){ref-type="table"}). Thus, the distinct changes in breastmilk leukocyte levels and properties during mastitis could be used as novel diagnostic tools for this condition, in which early diagnosis is important for a successful treatment and the maintenance of breastfeeding for longer periods.^[@bib40],\ [@bib41],\ [@bib42]^ This is often not possible due to limited understanding of its causes, the variability in associated microorganisms^[@bib40],\ [@bib41],\ [@bib42]^ and lack of tests that assess the health status of the lactating breast. The measurement of leukocyte content and subtypes in breastmilk using FACS, together with assessment of milk cytokine profile and dominant microorganisms, could be used as novel diagnostic tools to allow fast treatment of mastitis and other breast conditions during lactation.

Different infections showed differential effects on breastmilk composition. Some infections related to a stronger humoral response, while others to a stronger cellular response ([Figure 4b](#fig4){ref-type="fig"}). The latter was particularly seen in breast infections, which in contrast to other infections, were accompanied by an increase in total cell content. Although in milder breast infections (sore breast and blocked duct), non-immune cell populations contributed to the increase in total cell content, in mastitis this increase was significantly associated with a leukocyte response ([Table 3](#tbl3){ref-type="table"}).

In addition to maternal infection, a small but significant breastmilk leukocyte response was observed when the infant had an infection, but the mother was asymptomatic. This finding is supported by a recent study from Riskin *et al.*^[@bib43]^ that also reported a response of breastmilk leukocytes to active infection of nursing infants. This further reinforces the potential of breastmilk leukocyte measurement by FACS to be used in assessment of the health status of both the breastfeeding mother and infant. While the mechanism behind the leukocyte movement into the breast during an infection of the infant is still unclear, exposure of the mother to the infant\'s infection may stimulate an immunological response in the mother that is manifested without evident symptomatology, but which influences breastmilk leukocyte content. A potential way for this to happen is during breastfeeding. During a milk ejection, duct pressure increases, milk ducts dilate and milk flows toward the nipple/baby\'s mouth. As oxytocin wears off, duct pressure decreases, milk ducts reduce in size and milk flows backwards,^[@bib44]^ likely together with saliva from the baby\'s mouth. This is a time when it is possible that microorganisms from the infant could be transferred back into the breast, most likely during a pause in suckling, stimulating a local immune response.

In addition to infection, the stage of lactation influenced breastmilk composition. With the exception of IgG concentration, significant decreases were seen in immunomodulatory biomolecules and leukocyte content from colostrum to mature breastmilk, consistent with previous reports.^[@bib35],\ [@bib36],\ [@bib37],\ [@bib38],\ [@bib39]^ From week 2 postpartum onwards, total cell content increased with lactation stage, but leukocyte content was maintained at a low baseline level across lactation under healthy conditions. This is in accordance with previous findings showing a leukocyte change early on from colostrum to mature breastmilk,^[@bib14],\ [@bib45],\ [@bib46],\ [@bib47]^ and with a recent study showing low levels of leukocytes in mature breastmilk under healthy conditions in a Chinese population.^[@bib48]^ Percentage cell viability did not change significantly across lactation, in contrast to immunoglobulins and lactoferrin, which were differentially affected during the course of lactation, in accordance with previous studies.^[@bib35],\ [@bib36],\ [@bib37],\ [@bib38],\ [@bib39]^ Involution milk showed marked increases in total cell content and biochemical immune factor concentrations, suggesting that involution influences the biochemical and total cellular, but not the leukocyte, content of breastmilk. This is in support of the notion that cells from the epithelial compartment mediate clearing of apoptotic cells via phagocytosis in the involuting gland.^[@bib49]^

Exclusive breastfeeding was associated with a higher baseline level of leukocytes in breastmilk under healthy conditions. This may be associated with overall suckling time on the breast, and suggests that infants that are non-exclusively breastfed receive not only lower breastmilk volumes, but also breastmilk that contains fewer leukocytes. The higher breastmilk baseline leukocyte levels in exclusively breastfeeding dyads may contribute to the lower incidence of infections observed in this group, further reinforcing the protective role of breastmilk leukocytes for the infant.^[@bib3],\ [@bib6],\ [@bib9]^

The rapid response of breastmilk leukocytes to infections of the mother and the infant suggests that this is a tightly regulated process aimed at conferring additional immunological support to the infant. In situations where individuals do not have ready access to medicine, particularly in developing countries, breastfeeding-mediated protection may be a determining factor in infant recovery and survival. Formula does not offer this protection and the ability to adjust to infant needs. Thus, these findings present new information that is relevant to updating public policy on early infant nutrition that maximizes immunological development and protection against infections. At the same time, they offer new grounds for examining the mechanisms behind the very low rates of symptomatic HIV and cytomegalovirus disease in infants exclusively breastfed by infected mothers despite exposure to virus-infected breastmilk leukocytes.^[@bib31],\ [@bib32]^ This suggests that the breast is a mucosal site preferentially sheltered from viral replication and/or the presence of anti-viral transmission agents in breastmilk that confer enhanced local virologic control and protection to the infant.^[@bib25]^ Future examination of these hypotheses and the immunological response of the cellular and biochemical components of breastmilk to mother HIV are warranted.

The lactating breast, being the only metabolically significant organ of the body, for which a medical test does not exist, is often subjected to infections, which are diagnosed late, misdiagnosed or remain untreated. This contributes to an early cessation of breastfeeding with adverse effects for both the mother and the infant. The detection of breastmilk leukocyte levels may be useful in the assessment of the health status of the lactating breast, and the breastfeeding woman and infant. Similar tests are routinely used by the dairy industry to assess the quality of bovine milk based on the detection of an increase in somatic cell count being indicative of intramammary infection (California mastitis test).^[@bib33],\ [@bib34]^ Our studies have further refined and extended this test to human lactation by demonstrating a specific increase in breastmilk leukocytes with infection of the breastfeeding mother and/or infant. The diagnostic potential of this method will be reinforced by establishment of associations between specific infections and milk leukocyte/biochemical composition. This could prove particularly useful in early, rapid and successful diagnosis of these infections and the underlying microorganism(s) as well as in assessing the effectiveness of a treatment. In addition, our data provide the basis for investigating the effect of other factors, such as the menstrual cycle^[@bib50]^ or nipple damage/duct obstruction associated with nipple piercing,^[@bib51]^ on the health status of the breast via measurement of breastmilk leukocyte content.

Methods
=======

Study design
------------

The study was approved by the Human Research Ethics Committee of The University of Western Australia. Twenty-one breastfeeding dyads were recruited for the study and provided written informed consent. The lactation spectrum ranged from day 1 to year 4 postpartum. Breastmilk samples (5--50 ml) were collected at the following stages of lactation: colostrum (days 1--4 postpartum, *N*=5), transitional milk (day 5 to week 3 postpartum, *N*=7) or mature breastmilk (week 4 postpartum and beyond, *N*=51), and were collected during any infection of the mother or the infant as well as prior and/or after recovery ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). The participants provided detailed description of the symptoms of the infections, which included organ-specific and general infections of the mother and/or the infant ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Infections were clinically diagnosed by the participant\'s general practitioner, and managed with appropriate treatment. Milk samples were aseptically collected in the morning using an electric breast pump (Medela AG, Baar, Switzerland) and kept in sterile polypropylene vials at ∼20 °C in the dark during transportation to the laboratory. Cellular analyses were conducted within 1--2 h of expression, while all other analyses were done in frozen (−80 °C) sample aliquots as described below. Total cells were isolated from breastmilk as described previously.^[@bib22]^ Total cell content and viability were determined with a Neubauer hemocytometer (BRAND, Wertheim, Germany) by Trypan Blue exclusion. Subsequently, cells were analyzed using FACS, immunofluorescence staining and immunoreactivity physiological tests.

Flow cytometry
--------------

The cell suspension was distributed in vials and cells were incubated for 30 min at 4 °C with fluorescent-labeled anti-human CD45 ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). For leukocyte subset analysis, fluorescent-labeled antibodies against CD45, CD3, CD4, CD8, CD19, CD56 and CD14 were combined ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). Cells were washed twice in 3% fetal bovine serum in phosphate-buffered saline (PBS) and incubated for 30 min at 4 °C with live/dead fixable far-red dead cell stain (Life Technologies, Mulgrave, VIC, Australia) as per manufacturer\'s instructions. Cells were fixed in 1% paraformaraldehyde/0.7% sucrose solution in PBS and analyzed with a FACS Calibur Flow Cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Further data analyses were done using FlowJo (<http://www.flowjo.com>). Respective isotype controls were used to standardize background fluorescence. A completely unstained sample was always prepared in which propidium iodine (Sigma-Aldrich, Castle Hill, NSW, Australia) was added to check for the cellular uniformity of the cell suspension. In cases where this sample contained non-cellular particles (such as cellular fragments or fat globules), propidium iodine was added in all other samples (stained and controls) of the same cell suspension and only the cellular component was considered in the analyses.

Immunostaining
--------------

The cell suspension was fixed in 1% paraformaraldehyde/0.7% sucrose solution in PBS. Cytospins on glass slides were generated using Shandon Cytospin 3 (Shanton) centrifuge at 40.7 g for 4 min, and incubated with fluorescent-labeled anti-human CD45 antibody ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}) for 1 h at room temperature under humid conditions. Cytospins were washed in PBS, incubated with 4′6-diamidino-2-phenylindole (1:100) for 15 min, mounted in Cytomation mounting medium (Dako Australia, Campbellfield, VIC, Australia) and observed using a Nikon A1Si confocal microscope. Data were collected using the Nikon NIS Elements software package (Melville, NY, USA).

Immunoreactivity of milk leukocytes
-----------------------------------

In cases of very high breastmilk leukocyte content (60--90% of total cells), typically when the mother was diagnosed with mastitis, a subsample of the isolated live breastmilk leukocytes was cultured in U-bottom cell culture 96-well plates (Sarstedt, Numbrecht, Germany) at 500 000 cells per well in RPMI basic medium (Gibco, Grand Island, NY, USA) supplemented with 5% human serum and 5% antibiotic/antimycotic (Invitrogen). Six to eight statistical replicates (wells) were created per condition, which included (1) control (cell suspension in the above medium), (2) antigen effect (addition of 1 μl per well of CEF peptide pool, Cat No. 3615-1, Mabtech, Nacka Strand, Sweden) and (3) PHA effect (addition of 5 μl per well of Leucoagglutinin PHA-L, Cat No. L-4144, Sigma-Aldrich). Cells were incubated at 37 °C and 5% CO~2~ for 5 days before (a) removal of a 50-μl aliquot of culture supernatant and storage at −20 °C for cytokine analyses, and (b) addition of BrdU-labeling solution for measurement of cell proliferation using a BrdU Cell Proliferation enzyme-linked immunosorbent assay kit (Colorimetric, Roche, Dee Why, NSW, Australia, Cat. No. 11 647 229 001) according to the manufacturer\'s instructions.

Cytokine measurements
---------------------

Cytokines were determined in culture supernatants obtained from the immunoreactivity tests using the BD Cytometric Bead Array Cytokine Kit (Becton Dickinson) for seven cytokines (IL-2, IL-4, IL-6, IL-10, IL-17A, tumor necrosis factor-α and interferon-γ), following the manufacturer\'s instructions and assaying samples in duplicate in 1:1 dilution. A five-parameter logistic model was used to convert the bead fluorescence intensities to analyte concentrations.

Enzyme-linked immunosorbent assay
---------------------------------

Immunoglobulin (sIgA, IgG and IgM) and lactoferrin breastmilk concentrations were measured by enzyme-linked immunosorbent assay in defatted acellular sample aliquots stored at −80 °C, as described previously.^[@bib52]^ The 96-well microtitre plates were coated with 250 μl per well of anti-human sIgA (37 °C, 1 h), IgG or IgM (4 °C, overnight) ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). Subsequently, 200 μl per well of blocking solution (0.05% Tween-20/PBS containing 1 mg ml^−1^ BSA for sIgA/lactoferrin; skim bovine milk for IgG/IgM) was added for 30 min. The stored breastmilk samples were thawed to room temperature and diluted in 0.05% Tween-20/PBS 5000 times for sIgA, 600 times for IgG and IgM, and 50 000 times for lactoferrin. After washing (0.05% Tween-20/PBS) three times, 200 μl per well of standard, sample or control were added in duplicates for an 1-h incubation at 37 °C. Washing was followed by addition of 200 μl per well of secondary antibody and incubation for 1 h at 37 °C ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). The dilution of the secondary antibody for sIgA/lactoferrin was done in 0.05% Tween-20/PBS containing 1 mg ml^−1^ BSA, whereas for IgG/IgM in 0.05% Tween-20/PBS. In the IgM assay, incubation with the secondary antibody was followed by three washes and subsequent incubation with 200 μl per well of NeutrAvidin-HRP for 1 h at 37 °C ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). After secondary/tertiary antibody incubation, washing and rinsing with deionised water, 200 μl per well of color reagent were added and incubated in the dark at room temperature for 10--30 min. The color reaction was stopped by addition of 100 μl per well of 3 M sulfuric acid and the plate was read at 405 nm using a BioTek PowerWave X5 plate reader (BioTek, Winooski, VT, USA). The recovery of a known amount of sIgA, IgG, IgM or lactoferrin added to milk samples was on average 100.6±2.9%. The inter-assay coefficient of variation was on average 3.6%.

Statistical analyses
--------------------

Statistical analyses were performed in R 2.9.0 1^[@bib53]^ using the base packages and libraries lattice,^[@bib54]^ nlme^[@bib55]^ and multcomp.^[@bib56]^ Results are presented as mean±s.e.m. unless otherwise specified, and *P*\<0.05 was considered significant. Linear mixed effects models were used to determine which of the response variables (leukocyte content (% of total cells), leukocyte content (per ml milk), total and viable cell contents (per ml milk), cell viability (% viable cells of total cells), sIgA, IgG, IgM and lactoferrin) were affected by milk type, lactation stage, health status of the mother/infant dyad and breastfeeding status (exclusive versus non-exclusive). All models included a grouping factor of dyad and a random effect of different baseline levels for each dyad. Where health status was included in a model, 'healthy\' was considered to be the reference level. To determine whether data transformation was required, comparisons were made between raw data, square root-transformed data and natural log-transformed data models. After fitting the univariate model for each predictor, diagnostic plots (fitted values versus standardised residuals; qq-plot of residuals) were examined. In cases where a transformation was obviously superior, this was used for all covariate models. Owing to the measured zeroes obtained for leukocyte content (% and per ml milk) of some samples, these variables were transformed using the additive constant 0.5 for both the square root and the log transformations.^[@bib57]^ Differences between colostrum, 'healthy\' and 'infection\' samples were tested for with a three-level categorical predictor of milk type. Differences between 'healthy\' samples and each of the infection types were tested using a five-level factor ('healthy\', 'breast\', 'baby\', 'cold\' and 'other\'), with the colostrum samples omitted. Differences between pre- and post-infection 'healthy\' samples were tested where data were available (*n*=7) by classifying 'healthy\' as a two-level factor ('pre\' and 'post). To determine whether there were interactions between the health status of the dyad and either lactation stage (age in weeks) or exclusive breastfeeding (yes/no) in mature breastmilk, interaction models were considered for each of these covariates separately. Infection status was considered as a two-level factor ('healthy\' and 'infection\'). Models were selected using backwards stepwise methods, starting with the main effects+interaction model. Where the interaction was significant, all main effects were retained in the model.

For the lactation stage model, analysis was restricted to records where the baby was under 60 weeks of age (*N*=46 records, for 15 participants), due to the scarcity of data beyond this point. The effect of viral antigens and PHA on proliferation rate in leukocyte cultures generated from two samples of mastitic breastmilk was also assessed using linear mixed effects models. Separate models were used for each response variable, with replicate as the grouping variable and a random effect of different baseline effects per replicate. Tukey\'s HSD test was used to test all pairwise comparisons between the three treatments (control, viral antigen and PHA). Multivariate patterns in the immune markers (sIgA, IgG, IgM and lactoferrin) and three cellular measures (total cell and leukocyte contents, % leukocytes) were investigated analytically using singular value decomposition principal components analysis on scaled and centered data and graphically using biplots. This enabled comparisons between the conditions that were seen infrequently in this study.
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###### 
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![Maternal and/or infant infections stimulate a breastmilk leukocyte response. (**a**) Reduction of CD45^+^ leukocyte numbers from colostrum to a low baseline level in transitional and mature breastmilk. A breastmilk CD45^+^ (green) leukocyte is shown; blue: nucleus; scale bar: 2.5 μm. (**b**--**d**) Effect of maternal or infant infections on breastmilk cells in selected examples (**b**), and in the overall study cohort (*N*=21) (**c**), and changes during lactation (**d**) (blue: healthy dyad; red: under infection). Local regression (loess) smoothers show the overall pattern in the data. In the mastitis example in b, the insert shows the leukocyte content of breastmilk collected on the same expression from the other non-mastitic breast.](cti20131f1){#fig1}

![Mastitis-specific breastmilk leukocyte subpopulations and properties. (**a**) Breastmilk collected from women with mastitis contained distinct leukocyte subpopulations, including monocytes, macrophages, T helper cells, cytotoxic T cells, NK (natural killer) cells and B cells. These cells responded to viral antigen and PHA stimulation *in vitro* via increased proliferation (**b**) and production of cytokines (**c**). \**P*\<0.05, \*\**P*\<0.01.](cti20131f2){#fig2}

![Maternal and/or infant infections stimulate a breastmilk humoral response. (**a**) Effect of maternal or infant infections on breastmilk biochemical content (sIgA, IgG, IgM and lactoferrin) in the overall study cohort (*N*=21). (**b**) Changes of the breastmilk biochemical content during lactation under healthy conditions (blue) and under infection (red). Local regression (loess) smoothers show the overall pattern in the data.](cti20131f3){#fig3}

![Interactions between breastmilk components in relation to specific infections, stage of lactation and exclusivity of breastfeeding. (**a**) Biplots illustrating the relationships between seven breastmilk immune markers as determined from a PCA. The first two components (PC1 and PC2) are shown in the top plot, and the second and third components (PC2 and PC3) are seen in the middle plot. The combination of these two plots provides a three-dimensional representation of the multivariate data. Dots illustrate the individual records, and the vectors indicate the relative weights of the markers on each of the principal components. Vector labels include: 'Leukocyte\': leukocytes per ml milk, 'total cell\': total cells per ml milk, 'c\': colostrum, '•\': healthy, 'M\': mastitis, 'R\': recovering mastitis, 'B\': other breast conditions, 'eye\' and 'ear\': maternal eye and ear infections, respectively, 'W\': weaning, 'P\': periods, 'T\': vaginal thrush, 's\': other infections of the mother or baby. Red lines show the relative weights of each of the measures on each of the components. (**b**) Effect of breastfeeding status (exclusive, non-exclusive) on milk leukocyte content under healthy and infection conditions.](cti20131f4){#fig4}

###### Total cell, leukocyte, immunoglobulin (sIgA, IgG, IgM) and lactoferrin contents of human breastmilk at different stages of lactation, and responses to infections of the mother/infant dyad

  *Breastmilk component*                                *Health status*   *Colostrum*[a](#t1-fn3){ref-type="fn"}   *Transitional milk*[b](#t1-fn4){ref-type="fn"}     *Months 1--3*      *Months 4--6*      *Months 7--9*     *Months 10--12*         *Year 2*        *Late lactation*[c](#t1-fn5){ref-type="fn"}   *Involution milk*[d](#t1-fn6){ref-type="fn"}
  ---------------------------------------------------- ----------------- ---------------------------------------- ------------------------------------------------ ------------------- ------------------ ----------------- -------------------- ------------------- --------------------------------------------- ----------------------------------------------
  Total cells[e](#t1-fn7){ref-type="fn"} per ml milk        Healthy                 110 000--2 250 000                            113 492--883 333                  228 395--255 769    40 000--588 542    97 500--433 333   706 667--1 066 667   75 926--1 075 000               633 333--3 357 143                                 2 600 000
                                                           Infection                       ---                                        183 333                       50 000--2 867 383   115 278--321 918   37 000--504 951   437 500--1 000 000   60 714--1 708 333                49 166--1 166 667                                    ---
  \% Leukocytes                                             Healthy                     13.2--70.4                                   0.0--1.65                         0.07--0.45          0.0--1.52          0.0--1.09          0.08--0.1            0.0--0.06                        0.0--0.55                                        0.0
                                                           Infection                       ---                                          18.8                           0.72--90.5          1.1--33.9         1.08--93.6             \> 3             2.13--71.7                       4.27--10.8                                        ---
  Leukocytes^e^ per ml milk                                 Healthy                  32 175--784 080                                  0--3450                           160--1151           0--1025            0--1063            707--853             0--288                          0--13 750                                         0
                                                           Infection                       ---                                         34 467                        2400--2 594 982     2164--109 130      1065--472 634        \> 30 000          1293--759 834                    3127--49 817                                       ---
  sIgA (μg ml^−1^)                                          Healthy                     1428--2178                                   131--1096                          534--1276           257--960          496--1350          401--1044            137--1243                        976--1991                                        1761
                                                           Infection                       ---                                          922                             36--1418           652--1711          611--1509           714--789            173--2002                       1657--1906                                        ---
  IgG (μg ml^−1^)                                           Healthy                     5.3--12.2                                     2.8--9.7                          6.4--12.4          4.6--10.8          4.0--16.4          5.0--16.1            4.0--10.4                        4.6--17.8                                        22.9
                                                           Infection                       ---                                          13.0                            6.6--17.1          4.8--10.1          5.6--14.4           7.6--8.8            2.3--25.9                        9.4--13.4                                        ---
  IgM (μg ml^−1^)                                           Healthy                     16.2--56.1                                   8.2--29.8                         10.6--14.9          6.5--11.6          4.2--23.7          8.8--23.3            2.9--13.0                        7.1--23.1                                       100.4
                                                           Infection                       ---                                          10.2                            4.5--19.8          10.1--15.4        12.6--21.8          14.4--19.3           5.9--31.1                       10.5--23.5                                        ---
  Lactoferrin (g l^−1^)                                     Healthy                      6.3--7.7                                     2.1--5.2                          2.5--2.9            1.9--3.7          1.3--4.0            1.2--3.9            2.3--4.5                         3.3--5.8                                         6.2
                                                           Infection                       ---                                          4.3                             2.9--3.7            2.0--3.7          1.6--3.3            1.2--3.6            2.1--4.6                         4.6--5.6                                         ---

Abbreviation: sIgA, secretory IgA.

(h=healthy and i=infection).

Colostrum was defined as breastmilk collected between days 0--4 postpartum.

Transitional milk was defined as breastmilk collected between day 5 and week 3 postpartum.

Late lactation was defined as the period between months 25 and 48 postpartum.

Involution milk was collected 5 days after baby weaned off breastmilk (month 38 postpartum).

Total cells per ml and leukocytes per ml refer to total viable cells per ml and viable leukocytes per ml, respectively.

###### Statistical comparison of the levels of measured variables between milk samples grouped by type (colostrum versus mature breastmilk from healthy mother/infant dyads) or health status of the mother/infant dyad (healthy versus under infection), taking into account individual differences

  *Response*                                                      *Transform*    *Healthy (mature milk)Value*   *Under infection (mature milk)*   *Colostrum*            
  ------------------------------------------------------------ ----------------- ------------------------------ --------------------------------- ------------- -------- ---------
  Total cell content (per ml milk)                                  Log~e~       12.8                           −0.3                              0.271         0.5      0.326
  Viable cell content (per ml milk)                                 Log~e~       12.8                           −0.3                              0.253         0.5      0.353
  Leukocyte content[a](#t2-fn3){ref-type="fn"} (per ml milk)    Log~e~(*x*+0.5)  3.8                            5.9                               \<0.001       7.2      \<0.001
  \% Total cell viability (of total cells)                           None        97.8                           −1.5                              0.043         −2.6     0.056
  \% Leukocytes[a](#t2-fn3){ref-type="fn"} (of total cells)     Log~e~(*x*+0.5)  −0.25                          2.5                               \<0.001       3.6      \<0.001
  sIgA (μg ml^−1^)                                                   None        860.7                          169.9                             0.034         1288.5   \<0.001
  IgG (μg ml^−1^)                                                   Log~e~       2.01                           0.22                              0.048         0.07     0.710
  IgM (μg ml^−1^)                                                   Log~e~       2.49                           0.064                             0.606         0.864    \<0.001
  Lactoferrin (g l^−1^)                                              None        3.41                           −0.08                             0.658         3.88     \<0.001

Abbreviation: sIgA, secretory IgA.

*P*-values compare each group with the 'Healthy (mature milk)\' group.

For leukocyte content and percentage, the data were transformed using the additive constant 0.5 for both the square root and the log transformations owing to the zeroes in the data.^[@bib57]^

###### Effects of different types of infection on breastmilk cellular and biochemical composition

  *Response*                                                                     *HealthyValue*   *Infant only*   *Breast-related*   *Cold*   *Other infections*                           
  ------------------------------------------------------------------------------ ---------------- --------------- ------------------ -------- -------------------- ------ --------- ------ ---------
  Total cell content (per ml milk) (log~e~)                                      12.8             −0.9            0.127              0.6      0.133                −0.6   0.094     −0.4   0.348
  Viable cell content (per ml milk) (log~e~)                                     12.8             −0.9            0.123              0.6      0.143                −0.6   0.085     −0.4   0.345
  Leukocyte content[a](#t3-fn3){ref-type="fn"} (per ml milk) (log~e~(*x*+0.5))   3.7              4.3             0.046              6.7      \<0.001              6.1    \<0.001   5.9    0.0004
  \% Total cell viability (of total cells)                                       97.8             −0.9            0.571              −1.7     0.093                −2.1   0.025     −0.2   0.834
  \% Leukocytes[a](#t3-fn3){ref-type="fn"} (of total cells) (log~e~(*x*+0.5))    −0.3             1.1             0.064              3.2      \<0.001              2.8    \<0.001   2.1    \<0.001
  sIgA                                                                           858              88              0.632              174      0.155                144    0.197     302    0.042
  IgG (log~e~)                                                                   2.02             0.07            0.738              0.58     0.0003               0.04   0.758     0.12   0.481
  IgM (log~e~)                                                                   2.49             0.21            0.474              0.05     0.796                0.02   0.913     0.16   0.493
  Lactoferrin                                                                    3.4              −0.2            0.638              −0.1     0.787                −0.1   0.654     0.1    0.766

Abbreviation: sIgA, secretory IgA.

Groups include: infant-only infection (*N*=3), breast-related infection (*N*=9), cold (*N*=12), other organ-specific infections (eye, ear, vaginal, urinary tract and gastrointestinal infections; *N*=6) and no infection/healthy (*N*=28). *P*-values compare infection groups with the 'Healthy\' group.

For leukocyte content and percentage, the data were transformed using the additive constant 0.5 for both the square root and the log transformations owing to the zeroes obtained.^[@bib57]^

[^1]: Current address: School of Health Sciences, The University of Notre Dame Australia, 33 Phillimore Street, Fremantle, Western Australia (PO Box 1225, Fremantle, 6959), Australia.
